CRMD

AI Memo

CorMedix

As of 2026-05-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q1 beat and FY2026 guidance raise • 2026-05-14

Expected move: +65%

Biggest risk

The re-rating may already have captured much of the near-term earnings surprise, coverage is thin, and execution risk remains around utilization durability, supply/manufacturing, and the timing of longer-dated pipeline milestones [#10-Q-2026-05-14].

Invalidation

Break below $7 or thesis failure.

What would change my mind?

The Q1 print was a clear operating beat, management raised 2026 guidance, and the company still has multiple longer-dated upside levers in REZZAYO and DefenCath expansion [#8-K-2026-05-14] [#10-Q-2026-05-14].

Research note

Recommendation

—

Confidence

medium

As of

2026-05-29

Base target

$14

p=50%

Bull target

$17

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

REZZAYO prophylaxis sNDA and 2027 launch optionality
DefenCath TPN study enrollment and manufacturing execution
The Q1 print was a clear operating beat, management raised 2026 guidance, and the company still has multiple longer-dated upside levers in REZZAYO and DefenCath expansion [#8-K-2026-05-14] [#10-Q-2026-05-14].

BearKey bullets

Analyst revision coverage is unavailable here, so post-print expectations may be less validated than the headline price move implies.
Manufacturing or alternate-supplier qualification issues could pressure DefenCath supply continuity or margins.
Outpatient dialysis utilization and sales-allowance assumptions may not hold at the elevated Q1 level.

WatchKey bullets

Q1 beat and FY2026 guidance raise

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $14 (p=50%)

Bull/Bear spread: +108% / -20%

Vs latest close: Bull +108% · Base +65% · Bear -20%

Scenario probabilities

Bull Target: $17 (p=25%)Base Target: $14 (p=50%)Bear Target: $7 (p=25%)

Commentary

Primary-source earnings evidence was constructive and the post-release news flow was positive, but the packet has no analyst revision data and no social context, so this remains a monitored rerating view rather than a high-conviction multi-quarter call.

As of 2026-05-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

REZZAYO prophylaxis sNDA and 2027 launch optionality
DefenCath TPN study enrollment and manufacturing execution

Scenarios

Bull Target (Scenario probability)

$17 / p=25% prob

Base Target (Scenario probability)

$14 / p=50% prob

Bear Target (Scenario probability)

$7 / p=25% prob

Price $8 as of 2026-06-02

Nearest Scenario: Bear (∆ 20%)

Targets vs latest close: Bull +108% · Base +65% · Bear -20%

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-14
Q1 beat and FY2026 guidance raise
CorMedix reported strong Q1 2026 revenue and adjusted EBITDA, then raised full-year 2026 net revenue and adjusted EBITDA guidance; the quarter benefited from stronger DefenCath utilization and a favorable change in estimate for sales allowances [#8-K-2026-05-14].
Prob 95.00% • Move 11.00% • Priced-in 78.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

REZZAYO prophylaxis sNDA and 2027 launch optionality
2026-12-31
Management said the ReSPECT phase III topline readout was positive and expects an sNDA submission in the second half of 2026, with a possible launch for the expanded prophylaxis indication in 2027 [#8-K-2026-05-14].
Prob 65% • Move 15% • Priced-in 40%
DefenCath TPN study enrollment and manufacturing execution
2028-12-31
The ongoing Phase 3 taurolidine/heparin catheter lock study in TPN patients is still enrolling, and the 10-Q points to continued supplier qualification and capacity planning work that can affect execution and supply continuity [#10-Q-2026-05-14].
Prob 55% • Move 8% • Priced-in 35%

Risks

Analyst revision coverage is unavailable here, so post-print expectations may be less validated than the headline price move implies.
Manufacturing or alternate-supplier qualification issues could pressure DefenCath supply continuity or margins.
Outpatient dialysis utilization and sales-allowance assumptions may not hold at the elevated Q1 level.
Regulatory or enrollment delays could push out the REZZAYO sNDA timeline or the TPN study readout.

Peers

Symbol	Summary
PROK	Same-sector small-cap anchor, but it is more development-stage and binary than CorMedix; useful mainly as a risk-appetite and valuation comparator rather than a true operating peer.
CLYM	Another small-cap biotech comparator in the same sector, but it is more pipeline/event driven and less cash-generative than CorMedix.
BBOT	A nearby market-cap biotech anchor, yet still much more clinical-stage and less directly comparable to CorMedix's current commercial revenue profile.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-29

AI Stock Memo: CRMD - CorMedix - RankAlpha